WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H341011
CAS#: 107667-60-7
Description: Polaprezinc is an orally bioavailable chelate composed of zinc and L-carnosine, with potential gastroprotective, anti-oxidant, anti-ulcer and anti-inflammatory activities. Upon administration, polaprezinc increases the expression of various anti-oxidant enzymes, such as superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV) in the gastric mucosa, which protect cells against reactive oxygen species (ROS).
Hodoodo Cat#: H341011
Name: PolapreZinc
CAS#: 107667-60-7
Chemical Formula: C9H12N4O3Zn
Exact Mass: 288.02
Molecular Weight: 289.600
Elemental Analysis: C, 37.33; H, 4.18; N, 19.35; O, 16.57; Zn, 22.58
Synonym: Polaprezinc; Z 103.
IUPAC/Chemical Name: catena-Poly(zinc-mu-(beta-alanyl-L-histidinato(2(-))-N,N(sup N),O:N(sup tau)))
InChi Key: IGXZLYMCFZHNKW-FJXQXJEOSA-L
InChi Code: InChI=1S/C9H14N4O3.Zn/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6;/h4-5,7H,1-3,10H2,(H3,11,12,13,14,15,16);/q;+2/p-2/t7-;/m0./s1
SMILES Code: O=C1[C@@H](N2C(CC[NH2][Zn]2O1)=O)CC3=CN=CN3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 289.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Sakae K, Yanagisawa H. Zinc-L-Carnosine Complex (Polaprezinc) for the Treatment of Binge Eating: Three Case Reports. J Clin Psychopharmacol. 2017 Dec;37(6):734-736. doi: 10.1097/JCP.0000000000000784. PubMed PMID: 28926352.
2: Ozbayoglu A, Sonmez K, Karabulut R, Turkyilmaz Z, Poyraz A, Gulbahar O, Basaklar AC. Effect of polaprezinc on experimental corrosive esophageal burns in rats. Dis Esophagus. 2017 Nov 1;30(11):1-6. doi: 10.1093/dote/dox104. PubMed PMID: 28881910.
3: Ye J, Zhang Z, Zhu L, Lu M, Li Y, Zhou J, Lu X, Du Q. Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma. Mol Med Rep. 2017 Oct;16(4):5523-5528. doi: 10.3892/mmr.2017.7262. Epub 2017 Aug 16. PubMed PMID: 28849143.
4: Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev. 2017 Jul 31;7:CD012744. doi: 10.1002/14651858.CD012744. Review. PubMed PMID: 28759701.
5: Liu Z, Xie W, Li M, Teng N, Liang X, Zhang Z, Yang Z, Wang X. Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. Basic Clin Pharmacol Toxicol. 2017 Dec;121(6):480-486. doi: 10.1111/bcpt.12841. Epub 2017 Jul 25. PubMed PMID: 28667794.
6: Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, Li JS, Ren JL, Zou YY, Li YQ, Ji F, Fang JY, Qian JM. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One. 2017 Apr 13;12(4):e0175625. doi: 10.1371/journal.pone.0175625. eCollection 2017. PubMed PMID: 28407007; PubMed Central PMCID: PMC5391070.
7: Ooi TC, Chan KM, Sharif R. Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent? Nutr Cancer. 2017 Feb-Mar;69(2):201-210. doi: 10.1080/01635581.2017.1265132. Epub 2017 Jan 17. Review. PubMed PMID: 28094570.
8: Byun SJ, Lim TJ, Lim YJ, Seo JG, Chung MJ. In vivo effects of s-pantoprazole, polaprenzinc, and probiotic blend on chronic small intestinal injury induced by indomethacin. Benef Microbes. 2016 Nov 30;7(5):731-737. Epub 2016 Nov 8. PubMed PMID: 27824272.
9: Odawara S, Doi H, Shikata T, Kitajima K, Suzuki H, Niwa Y, Kosaka K, Tarutani K, Tsujimura T, Kamikonya N, Hirota S. Polaprezinc protects normal intestinal epithelium against exposure to ionizing radiation in mice. Mol Clin Oncol. 2016 Oct;5(4):377-381. Epub 2016 Aug 8. PubMed PMID: 27699029; PubMed Central PMCID: PMC5038609.
10: Mizukami Y, Sato J, Nihei S, Kashiwaba M, Kudo K, Okuyama H, Tamura K. [The Effectiveness of Polaprezinc Preparation for Taste Alteration in Cancer Chemotherapy]. Gan To Kagaku Ryoho. 2016 Aug;43(8):979-83. Japanese. PubMed PMID: 27539040.
11: Higashimura Y, Takagi T, Naito Y. [Zinc and gastrointestinal disorders]. Nihon Rinsho. 2016 Jul;74(7):1121-5. Japanese. PubMed PMID: 27455800.
12: Miyata S. [Supplementation of trace elements in the general medicine]. Nihon Rinsho. 2016 Jul;74(7):1074-86. Review. Japanese. PubMed PMID: 27455795.
13: Hayashi H, Kobayashi R, Suzuki A, Yamada Y, Ishida M, Shakui T, Kitagawa J, Hayashi H, Sugiyama T, Takeuchi H, Tsurumi H, Itoh Y. Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy. Med Oncol. 2016 Aug;33(8):91. doi: 10.1007/s12032-016-0795-z. Epub 2016 Jul 14. PubMed PMID: 27418192; PubMed Central PMCID: PMC4945687.
14: Tsutsumi K, Kaname T, Shiraishi H, Kawashiri T, Egashira N. Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity. J Pharmacol Sci. 2016 Jun;131(2):146-9. doi: 10.1016/j.jphs.2016.04.019. Epub 2016 Apr 26. PubMed PMID: 27262900.
15: Suzuki A, Kobayashi R, Shakui T, Kubota Y, Fukita M, Kuze B, Aoki M, Sugiyama T, Mizuta K, Itoh Y. Effect of polaprezinc on oral mucositis, irradiation period, and time to discharge in patients with head and neck cancer. Head Neck. 2016 Sep;38(9):1387-92. doi: 10.1002/hed.24446. Epub 2016 Mar 22. PubMed PMID: 27002591.
16: Kadoya H, Uchida A, Kashihara N. A Case of Copper Deficiency-Induced Pancytopenia With Maintenance Hemodialysis Outpatient Treated With Polaprezinc. Ther Apher Dial. 2016 Aug;20(4):422-3. doi: 10.1111/1744-9987.12398. Epub 2016 Mar 7. PubMed PMID: 26948531.
17: Ooi TC, Chan KM, Sharif R. Zinc Carnosine Inhibits Lipopolysaccharide-Induced Inflammatory Mediators by Suppressing NF-κb Activation in Raw 264.7 Macrophages, Independent of the MAPKs Signaling Pathway. Biol Trace Elem Res. 2016 Aug;172(2):458-64. doi: 10.1007/s12011-015-0615-x. Epub 2016 Jan 9. PubMed PMID: 26749414.
18: Yanase K, Funaguchi N, Iihara H, Yamada M, Kaito D, Endo J, Ito F, Ohno Y, Tanaka H, Itoh Y, Minatoguchi S. Prevention of radiation esophagitis by polaprezinc (zinc L-carnosine) in patients with non-small cell lung cancer who received chemoradiotherapy. Int J Clin Exp Med. 2015 Sep 15;8(9):16215-22. eCollection 2015. PubMed PMID: 26629136; PubMed Central PMCID: PMC4659025.
19: Samborski P, Grzymisławski M. The Role of HSP70 Heat Shock Proteins in the Pathogenesis and Treatment of Inflammatory Bowel Diseases. Adv Clin Exp Med. 2015 May-Jun;24(3):525-30. doi: 10.17219/acem/44144. Review. PubMed PMID: 26467144.
20: Kobayashi H, Abe M, Okada K, Tei R, Maruyama N, Kikuchi F, Higuchi T, Soma M. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Nutrients. 2015 May 15;7(5):3783-95. doi: 10.3390/nu7053783. PubMed PMID: 25988769; PubMed Central PMCID: PMC4446779.
